admin – Page 21 – Swanson Reed | Specialist R&D Tax Advisors

IACMI: Leading the Charge in Composites Research and Development

The Institute for Advanced Composites Manufacturing Innovation (IACMI) is at the forefront of technological research and development in the composites manufacturing industry. Recently, IACMI announced a funding renewal from the U.S. Department of Energy (DOE) that will support its continued efforts to accelerate commercialization and decarbonization through advanced composites technologies.

Over the past six years, IACMI has managed over 60 collaborative and industry-led technical projects, representing over $200 million in R&D investment, catalyzed more than 25 new composites-based products to commercialization, supported the creation of 3,000 jobs at composite materials and parts manufacturers, and spurred investment of $75 million in five states for R&D and scale-up facilities.

One such successful project was IACMI’s collaboration with Volkswagen of America to redesign and validate a liftgate for the VW Atlas using composites, reducing its weight by 35% and lowering its cost by 9% compared with steel. Another example is the scaling, manufacture and testing of novel thermoplastic wind turbine blades that are recyclable and lower in cost.

IACMI’s working groups are dedicated to R&D for high rate aerostructures fabrication, digital twins, future mobility, wind energy, infrastructure and construction, and the circular economy through recycling and novel materials.

Furthermore, IACMI has invested in a shared infrastructure for open-access composites manufacturing R&D capabilities with state economic development organizations and the DOE. These shared scale-up facilities include the Manufacturing Demonstration Facility at Oak Ridge National Laboratory, the Carbon Fiber Technology Facility at ORNL, the Fibers and Composites Manufacturing Facility at the University of Tennessee, Knoxville, the Laboratory for Systems Integrity and Reliability at Vanderbilt University, the Composites Laboratory at the University of Dayton Research Institute, the Composites Manufacturing & Simulation Center at Purdue University, the IACMI Scale-Up Research Facility (SuRF) managed by Michigan State University, and the Composites Manufacturing Education and Technology Facility (CoMET) at National Renewable Energy Laboratory (NREL).

IACMI’s continued efforts in the composites manufacturing industry have earned it the distinction of being the first clean energy institute to be renewed by the DOE, and it is one of 16 national Manufacturing USA institutes established to catalyze advanced manufacturing and materials applications. IACMI aims to further its mission by attracting startups and small enterprises, as well as large enterprises, national labs and universities.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

REGENT Unveils Full-Scale Model of All-Electric Seaglider Prototype

REGENT, a company that is developing a revolutionary all-electric seaglider, recently unveiled a full-scale mock-up of its prototype. The company also announced plans to expand its global headquarters, which will include new manufacturing and test facilities. The expansion has the potential to fulfill $8 billion in commercial orders by 2025 at the headquarters in Rhode Island.

According to REGENT, its seaglider is the first vehicle to take off from a controlled hydrofoil to wingborne flight. The seaglider is designed with multiple redundancies in its all-electric distributed power system and automated flight software and sensor systems to provide operators with full situational awareness for navigation, object detection, and flight conditions.

The $50 million in funding has significantly accelerated the development of the seaglider prototype, including building and flying the first quarter-scale seaglider prototype to prove out the float-foil-fly mission. The cumulative learnings from more than a year of flight testing were used to inform the design of the full-scale seaglider. REGENT aims to deliver its product to market by the mid-decade, tailoring its vehicles to meet the diverse needs of its customers, including commercial transport, supply chain and logistics, and military defense applications.

REGENT’s seagliders are designed to revolutionize sustainable, maritime transportation in coastal communities, offering a fast, efficient, and emission-free solution. With 40% of the world’s population living in coastal communities, there is a dire need for a fundamentally new method of transportation to efficiently move people and cargo through coastal routes.

The seagliders will serve as a complementary addition, rather than a replacement, to traditional modes of maritime and airline transportation, which can be seamlessly integrated into customers’ existing fleets. Based on publicly validated data, REGENT’s studies show that its seagliders serve an $11 billion market that could swell to as much as $25 billion as battery technology advances.

REGENT envisions its vehicles to act as a bridge between coastal city centers, facilitating multi-modal transportation through coastal airports. The company has established a loyal customer base of major airlines and ferry operators, such as FRS in Germany, Ocean Flyer in New Zealand, and Southern Airways/Mokulele Airlines, who plan to deliver their first commercial passenger seagliders to once they hit the market. The seagliders will comprise the best features of both maritime and aviation transport, combining the speed and comfort of an airplane with the cost efficiency of a boat.

The new facility expansion in Rhode Island will support initial low-rate production and at-rate production to fulfill the $8 billion commercial backlog. With the electrification of ferries, aircraft, rail, and other modes of transportation, REGENT’s all-electric seagliders are an integral part of the future of sustainable, multi-modal mobility.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Resilient Lifescience Is Fighting Opioid Overdose with Tech

Resilient Lifescience, a startup based in Pittsburgh, is making waves in the fight against fatal opioid overdose with its wearable medical device. In 2021, over 5,000 people in Pennsylvania lost their lives to overdoses, and CEO Brad Holden was personally impacted by the epidemic after losing a family member to opioid use. He teamed up with CTO Charlie Proctor to develop a wearable patch that can detect and reverse overdoses using naloxone, an overdose-reversing drug.

The device can be worn on the abdomen and monitors the wearer’s vitals. If it detects an overdose, it automatically injects naloxone to prevent death. Resilient Lifescience has been working with harm reduction organizations in Western Pennsylvania and talking to people who have struggled with opioid use to develop the device.

The startup has also received support from life sciences-focused accelerators such as LifeX, as well as funding from the Richard King Mellon Foundation’s Social-Impact Investment Pitch Competition. Resilient Lifescience is now in the process of raising a seed round of $1.5 million to support its research and development.

Holden believes that technology will be a critical tool in combating the opioid epidemic, and the Resilient Lifescience device could save tens of thousands of lives per year. The startup plans to conduct a clinical study this summer and partner with a supervised injection facility by the beginning of 2024 to show that its device can detect overdoses in a real-world setting.

Resilient Lifescience’s mission to reduce opioid overdose deaths is an important one, and its innovative wearable medical device could make a significant difference in the lives of people struggling with opioid addiction. With its partnerships with harm reduction organizations and life sciences-focused accelerators, Resilient Lifescience is well-positioned to continue its research and development and bring its device to those who need it most.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Lumata Health and Prevent Blindness Join Forces to Tackle Mental Health Challenges for Americans with Vision Loss

Florida Patent of the Month - November 2021

Lumata Health, a healthcare startup that aims to prevent vision loss from chronic eye diseases, has partnered with Prevent Blindness, the leading volunteer eye health and safety organization in the US, to address barriers to care for patients. The partnership will initially focus on providing mental health resources to individuals with chronic eye diseases, including anxiety and depression. With over seven million Americans experiencing vision impairment and one in four adults with vision loss experiencing anxiety or depression, the partnership is timely and vital.

To kick off the partnership, Lumata Health and Prevent Blindness will collaborate on a training program for Lumata’s certified eye care coordinators. The program will focus on capacity building around mental health resources and support for individuals experiencing vision loss and blindness. Lumata’s care coordinators work directly with patients to ensure adherence to their doctor’s care plan and address barriers to care.

This partnership will enable Lumata’s team of care coordinators to connect with various resources in any given geographical area to support low vision patients. Lumata Health currently serves thousands of patients suffering from vision-threatening chronic eye conditions through partnerships with ophthalmology clinics and health systems. Patients supported by Lumata Health’s intelligent eye care management platform miss an average of 30% fewer appointments.

Prevent Blindness was founded over one hundred years ago, and together with its six state affiliates, advocates and engages millions of people each year to promote eye health and vision preservation. The organization’s services include public and professional education, advocacy, certified vision screening and training, community and patient service programs, and research.

The partnership between Lumata Health and Prevent Blindness will go a long way in addressing mental health issues among patients with chronic eye diseases. By providing impactful resources and support, the two organizations hope to prevent preventable blindness and preserve vision in the US. Follow Lumata Health and Prevent Blindness on their social channels for the latest news and information.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

B9Creations: Revolutionizing Osteoarthritis Research with Cutting-Edge Technology

For decades, researchers have struggled to find a cure for osteoarthritis, a disease that affects millions of people worldwide. However, Rapid City-based additive manufacturing solutions provider B9Creations is now partnering with a South Dakota Mines research team to find a solution to this debilitating condition.

Together, they are developing a “joint-on-a-chip” device – an evolution of “lab-on-a-chip” – that will allow researchers to study the complex interactions between cells in human joints. Using B9Creations’ 3D printing technology, the Mines research team has patented a breakthrough technology called CellWell, which, when combined with 3D-printed housing, enables the study of cartilage cells in a way that mimics their natural state. This unique combination of tools is offering new insights into the causes of osteoarthritis, which were impossible to gain before.

Scott Wood, Ph.D., an assistant professor in the NanoScience and Biomedical Engineering Department at Mines, and his students led the research and development of this groundbreaking technology, which they now utilize in their startup, CellField Technologies. According to Wood, osteoarthritis is not just a “wear and tear” disease, but rather an imbalance of the behavior of the cells in the joint.

CellWell technology uses a combination of nanotechnology, micropatterning, and mechanically-tunable thin-film composite materials to create an environment that allows cartilage cells to maintain their physiological nature without restricting their ability to be studied. Compared to competing technologies, CellWell can maintain the physiological cell shape and biomarker profile of chondrocytes for at least 28 days, four times as long as others.

The project has received funding from the National Science Foundation, the Governor’s Office of Economic Development, and DRACO, a South Dakota nonprofit organization that advises startup companies and entrepreneurs. The team’s technology is aimed at small to mid-sized pharmaceutical companies, who are most focused on finding cures for osteoarthritis.

Wood’s work has been recognized with a National Science Foundation CAREER Award, which is the most prestigious award for early-career faculty. He is one of four faculty at Mines to receive this award since 2015 and the second from the NanoScience and Biomedical Engineering Department. Wood was also a finalist in the South Dakota Governor’s Giant Vision Competition.

With the development of CellWell technology, B9Creations and the Mines research team are paving the way for a cure for osteoarthritis. By studying cartilage cells in a way that mimics their natural state, researchers will be able to gain new insights into the behavior of the cells in the joint, which will be invaluable in developing new treatments for this debilitating disease.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Revolutionizing Digestive Health: Oshi Health Takes Up $30M In Series B Funding

Digestive disorders affect 1 in 4 Americans and have a high economic burden, driving $135 billion in annual costs. Traditional GI care often leaves patients unsupported between visits, leading to prolonged suffering, high avoidable costs, and long wait times for appointments. But what if there was a way to address these issues and provide comprehensive care for digestive disorders? This is exactly what Oshi Health is aiming for.

Oshi Health, a virtual gastrointestinal care clinic, has recently raised $30 million in series B funding to scale up its technology and meet the growing demand from patients, employers, health plans, and provider groups. This brings their total funding to $59.5 million, and they have partnerships with health platform Solera Health and virtual care company Firefly Health.

Oshi Health is addressing issues including Crohn’s disease and ulcerative colitis, using a comprehensive approach with gastroenterologists, dietitians, behavioral health support, and care coordinators. Their virtual multidisciplinary care resulted in significantly higher levels of patient engagement, satisfaction, and symptom control, as per a prospective study sponsored by Oshi Health.

Moreover, the recent clinical study results are driving accelerated contracting with payers and employers to reimburse access to Oshi Health as a covered benefit. Oshi Health’s services also drove all-cause medical cost savings of $10,292 per patient in just six months, the study found.

The company connects users with an integrated care team consisting of GI specialists including board-certified gastroenterologists, registered dietitians, GI-specialized mental health clinicians, and nurse practitioners. Oshi Health’s approach is to get to the root causes of chronic digestive symptoms and help members understand their own dietary and psychological triggers through iterative treatment and response.

The company’s platform is currently available to over 20 million people as a preferred in-network virtual gastroenterology clinic for national and regional insurers as well as their employer customers. Oshi Health also partners with community GI practices in a collaborative hybrid model to extend access to care, including reimbursed access to dietary and behavioral therapies.

The new funding will accelerate the next phase of Oshi Health’s growth, to scale its clinical team nationwide and forge relationships with health plans, employers, channel partners, and provider groups. “Our investors are collectively funding the change-makers in the most crucial categories of healthcare,” said Sam Holliday, Oshi Health CEO. “They see the transformation opportunity and urgency in digestive care as clearly as we do, and we’re proud to have them back our mission to free millions of Americans from their struggle with digestive symptoms and conditions.”

Oshi Health’s success is part of a growing list of virtual-first companies focused on gastrointestinal care, and the sector is attracting more investment dollars. Ayble Health launched last year with $4.6 million in seed funding, and Salvo Health, a New York-based virtual health clinic focusing on specialty care for chronic gut conditions, nabbed $10 million in seed funding. Oshi Health’s unique care model, which provides comprehensive care and addresses chronic digestive symptoms, is revolutionizing digestive health.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Mobeus: Revolutionizing Telepresence and Self-Expression with Innovative Transparent Computing Technology

Missouri Patent of the Month - December 2021

Mobeus, a startup based in Sparta, New Jersey, is making waves in the tech world with its innovative product, Airglass. The product is a video and audio communications tool that enhances virtual meetings by using transparent computing. It is a user-centric computing scheme that separates hardware and software to convert desktop software into a transparent, glass-like layer, giving the user the impression of looking beyond the display screen. The company has submitted around 70 patents, with 12 already issued and being pursued internationally. The Airglass product serves as both a commercial product and a way to test the technology in the market.

Mobeus was founded when the COVID pandemic highlighted limitations in the existing telepresence systems. The founders began working towards something foundational that could be a product and a platform. The team figured out how to turn the whole front of the computer into an interactive 3D presentation and turn the entire display of the computer into immersive glass.

The company is using Airglass to take telepresence places it has never been before and believes that the product will revolutionize how people express their creativity. The user experience with Airglass isn’t as immersive as with virtual reality or augmented reality, but it meets consumers right where they are right now. The company does not think this technology will replace VR headsets; however, when using this technology, the screen becomes 3D instead of 2D, introducing a new way to operate the computer and a new way to communicate and collaborate.

Mobeus has 40 employees, with 10 of them living in New Jersey. The company’s funding came from some ultra-high net worth individuals and Accenture Ventures, according to Richie Etwaru, co-founder and chief creative officer at Mobeus. The company is now one of the most innovative startups in New Jersey, offering a great example of how a small startup with a big idea can disrupt an entire industry.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Laborie Medical Technologies takes the lead in diagnosing GERD with alpHaONE System

GERD, or gastroesophageal reflux disease, affects millions of people worldwide. Its diagnosis can be difficult, as current methods include invasive endoscopic exams and X-rays. But Laborie Medical Technologies is changing the game with their alpHaONE system—a wireless device that can be implanted in the esophagus and collect data for up to four days.

The alpHaONE system works by placing a small sensor capsule on the esophageal wall, a short distance from the stomach, and recording changes in pH levels over time. This data is then transmitted to a handheld device that logs the information and allows the user to document their meals, time spent lying down, and feelings of heartburn, coughs, or deep belches.

One of the standout features of the alpHaONE system is its ease of use. Patients can carry the handheld device with them wherever they go, making it easy to track their symptoms and lifestyle habits. Laborie also offers a virtual instruction program to help patients better understand how to use the device and interpret the data.

The New Hampshire-based company estimates that about 1 in 5 people in the U.S. may suffer from GERD. With the alpHaONE system, these patients can now receive a more accurate diagnosis and better manage their condition.

Laborie is a global medical technology company specializing in Gastroenterology, Urology & Urogynecology, and Obstetrics, Gynecology & Neonatal. Through the development and manufacture of high quality, high impact diagnostic and therapeutic products, Laborie consistently contributes to the improvement of patient outcomes.

The alpHaONE system is just one example of the many exciting developments happening in the world of medical research and development. As technology continues to advance, we can expect to see even more innovative solutions that will improve patient care and outcomes.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Red Way: A New Hope for Lincoln’s Struggling Airport – Exploring the Prospects of a New Ultra-Low-Cost Carrier

Stratodynamics Shows Pomise in Unmanned Aerial Turbulence Detection

Lincoln, Nebraska, a city known for its history and recreational facilities, has become a battleground for a new startup called Red Way, which has stepped up to fill the void left by legacy carriers withdrawing from the city. Red Way is an ultra-low-cost carrier that is aiming to operate twice-weekly flights to major cities across the United States.

Red Way’s modus operandi is unique, as it functions as a “virtual airline” by handling sales and bookings via a Red Way-branded website, while Florida-based charter operator Global Crossing Airlines will supply and operate the aircraft. The airline has already received revenue guarantees in the form of COVID-19 relief funds from the city and county, totaling $3 million.

Red Way’s business model is centered around leisure markets, which can be tricky given the impact of the COVID-19 pandemic on the travel industry. However, Red Way CEO Nickolas Wangler is confident that the company will succeed. The airline plans to fly to destinations such as Atlanta, Austin, Dallas, Las Vegas, Minneapolis, Nashville, and Orlando, and it aims to respond directly to consumer demand, meaning it will cancel routes that don’t resonate with passengers. In addition, Red Way plans to add more flights to warmer destinations in the US during the winter months.

Although the concept of Red Way seems promising, industry experts and bloggers have expressed concerns about its long-term viability. Some analysts have criticized the airline’s limited flight schedule and its pricing structure, which requires passengers to pay extra for additional services such as carry-ons and checked bags. Moreover, recent Department of Transportation data reveals that few people have been flying the new routes added by Red Way.

Despite the challenges, the airline is optimistic about its future. The company has a strong community backing, and it is hoping to cater to a demand for low-cost leisure travel to destinations that are currently not served by other carriers. Red Way’s first flight from Lincoln Airport is scheduled to depart for Orlando on June 16.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Miromatrix Reports Promising Results and Advances in Bioengineering Fully Transplantable Organs

Miromatrix Medical Inc. has released a corporate update along with their 2022 financial report. The company’s primary objective for the year ahead is the initiation of a Phase 1 clinical trial for miroliverELAP. This new bioengineered organ technology, which is focused on providing patients with acute liver failure access to fully transplantable organs, is a significant milestone that, once achieved, will provide vital validation. The company is also concentrating the majority of its resources on miroliverELAP™ to achieve the clearance for IND (investigational new drug) to enable testing by the end of 2023.

Miromatrix has a collaborative research agreement with Baxter International Inc. relating to miroliverELAP™, which it announced on February 1, 2023. miroliverELAP™ is a liver therapy which combines Miromatrix’ single-use bioengineered liver with Baxter’s PrisMax system. The Phase I clinical trial will look to treat patients suffering from acute liver failure. The company has also revealed that presentations have been selected for the American Transplant Congress in June 2023, which will relate to mirokidney and miroliverELAP™.

Miromatrix Medical is making significant progress in bioengineering fully transplantable human organs to address the shortage of available organs. The company’s focus on miroliverELAP™ and the initiation of a Phase 1 clinical trial for this technology is a major milestone that will provide validation for its bioengineering technology platform.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.